A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
Phase 2
Terminated
- Conditions
- Diabetes MellitusDiabetic RetinopathyDiabetic Macular Edema
- Interventions
- Drug: THR-687 dose level 1Drug: THR-687 dose level 2Drug: THR-687 selected dose level
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Oxurion
- Target Recruit Count
- 16
- Registration Number
- NCT05063734
- Locations
- 🇱🇻
Pauls Stradins Clinical University Hospital, Riga, Latvia
🇺🇸Salehi Retina Institute Inc., Huntington Beach, California, United States
🇺🇸Retina Center of Texas, Southlake, Texas, United States
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
Phase 2
Completed
- Conditions
- Diabetes MellitusDiabetic RetinopathyDiabetic Macular Edema
- Interventions
- Drug: THR-149 dose level 1Drug: THR-149 dose level 2Drug: THR-149 dose level 3Drug: THR-149 0.13mgDrug: THR-149 0.13mg + aflibercept 2mg
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Oxurion
- Target Recruit Count
- 135
- Registration Number
- NCT04527107
- Locations
- 🇺🇸
Northern California Retina Vitreous Associates Medical Group, Inc., Mountain View, California, United States
🇺🇸Blue Ocean Clinical Research, Clearwater, Florida, United States
🇺🇸Retina Associates of Cleveland, Inc, Cleveland, Ohio, United States
A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
Phase 2
Completed
- Conditions
- Diabetic RetinopathyMacular EdemaDiabetes Mellitus
- Interventions
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Oxurion
- Target Recruit Count
- 70
- Registration Number
- NCT03499223
- Locations
- 🇫🇷
Centre Rétine Gallien, Bordeaux, France
🇫🇷CHU Dijon, Dijon, France
🇫🇷Hôpital Privé La Louvière, Lille, France
© Copyright 2025. All Rights Reserved by MedPath